Doug Hoffman

Not #AHS2020 related, but in headache news: Cefaly Technology have announced a partnership with Azova’s Collaborative Clinical Care Platform to expand access to the Cefaly Dual migraine device. lnkd.in/dCrDX6u

#AHS2020: Data on patients with chronic migraine receiving treatment with onabotulinumtoxinA who have been prescribed a CGRP medication suggests they are safe and effective for those who require additional preventive treatment. lnkd.in/dkqCZGM

These data add to the already active and ongoing discussion surrounding the use of preventive medications in the youth population with migraine. #AHS2020 lnkd.in/dgjTSYb

"These novel findings have direct implications for practice guidelines. In fact, in 2019, the latest guidelines were published in Neurology, specifically requesting data on long-term follow-up." – Scott Powers, PhD, ABPP #AHS2020 lnkd.in/dDdppuN

This finding implies that menarche may be a time to consider an alteration in the therapeutic approach. lnkd.in/eRNSeWS

To glean some perspective for the clinical community about this new PET tracer approval, we spoke to Howard Fillit, MD, founding executive director and chief science officer, Alzheimer’s Drug Discovery Foundation. lnkd.in/evStDgf

The FDA accepted for review the company’s sNDA for its amantadine (Gocovri) extended-release capsules as a treatment for off episodes in patients with Parkinson disease who are receiving levodopa-based therapy. lnkd.in/eNEwhEF

Findings from the CONTAIN study suggest that yoga, when utilized as add-on therapy, has a superior impact for patients with migraine compared to medical therapy alone. lnkd.in/exfE5wH

To find out more about the device itself and how this MICC technology can offer clinicians more than standard DBS tech, we reached out to Vitek, who offered his perspective and experience with the device. lnkd.in/edssTYu